ACS Medicinal Chemistry Letters·15 SepCrystal Structure of the Sigma‑2 Receptor Complexed with Investigational Drug Zervimesine (CT1812)MechanismsPaper
AAIC 2025 Abstract·9 JanPlasma proteomic analysis of a biomarker‐defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in Alzheimer's disease participantsTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecBaseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)Trial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecZervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p‐tau217 Across the Mild‐to‐Moderate AD SpectrumTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecExploratory CSF proteomic analysis of a pre‐specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer’s disease patients treated with zervimesineTrial in peopleInterventionsPaper